Bionik Laboratories Corp. Stock
Equities
BNKL
US09074A2087
Medical Equipment, Supplies & Distribution
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
2023 | Bionik Laboratories Corp. Announces Executive Changes | CI |
2023 | Bionik Laboratories Corp. Reports Earnings Results for the Full Year Ended March 31, 2023 | CI |
Sales 2022 | 1.27M 1.74M | Sales 2023 | 1.81M 2.46M | Capitalization | 2.8M 3.82M |
---|---|---|---|---|---|
Net income 2022 | -10M -13.65M | Net income 2023 | -4M -5.46M | EV / Sales 2022 | 0.17 x |
Net cash position 2022 | 1.99M 2.72M | Net Debt 2023 | 1.98M 2.71M | EV / Sales 2023 | 2.65 x |
P/E ratio 2022 |
-0.21
x | P/E ratio 2023 |
-0.56
x | Employees | 12 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 20% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Russo
CEO | Chief Executive Officer | 44 | 20-11-29 |
Michal Prywata
FOU | Founder | 33 | 10-01-07 |
Dan Gonsalves
DFI | Director of Finance/CFO | - | 21-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michal Prywata
FOU | Founder | 33 | 10-01-07 |
Director/Board Member | 68 | 17-08-31 | |
Richard Russo
CEO | Chief Executive Officer | 44 | 20-11-29 |
1st Jan change | Capi. | |
---|---|---|
-.--% | 12 | |
-2.67% | 187B | |
-1.61% | 106B | |
-4.43% | 66.9B | |
+0.74% | 49.45B | |
+16.62% | 48B | |
+4.06% | 40.84B | |
+3.61% | 26.48B | |
+1.40% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- BNKL Stock